Skip to main content
MACROGENICS INC logo

MACROGENICS INC — Investor Relations & Filings

Ticker · MGNX ISIN · US5560991094 LEI · 5493001KJQUA83L8MH79 US Manufacturing
Open in API
Filings indexed 894 across all filing types
Latest filing 2017-10-26 Director's Dealing
Country US United States of America
Listing US MGNX

About MACROGENICS INC

https://www.macrogenics.com/

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary antibody engineering platforms, including the DART (Dual-Affinity Re-Targeting) and TRIDENT technologies, to create novel product candidates. Its pipeline consists of investigational treatments such as monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific antibodies. MacroGenics maintains fully-integrated capabilities, from research and discovery through to GMP (Good Manufacturing Practice) manufacturing, to advance its portfolio of potential medicines for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2017-10-26 English
FORM 4
Director's Dealing
2017-09-07 English
FORM 4
Director's Dealing
2017-09-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 29, 2017, reporting the termination of a material definitive agreement between MacroGenics, Inc. and Janssen Biotech, Inc. It includes details about the termination notice, the impact on clinical trials, and rights reversion. The document also references a press release attached as an exhibit. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The content is a regulatory announcement about a material contract termination, which fits the category of Regulatory Filings (RNS). The document length is 4172 characters, which is relatively short and consistent with a regulatory filing rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-08-31 English
Regulatory Filings 2017
Regulatory Filings
2017-08-18 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 2, 2017, reporting the company's financial and operating results for the quarter ended June 30, 2017. It includes a press release as an exhibit announcing these results. The document is relatively short (3455 characters) and primarily serves as an announcement of the earnings release rather than containing detailed financial statements or substantive financial data itself. According to the rules, initial announcements of quarterly financial results are classified as Earnings Release (ER). The presence of a press release announcing quarterly results aligns with the ER category rather than a full interim report (IR) or annual report (10-K). Therefore, the appropriate classification is Earnings Release (ER) with high confidence.
2017-08-02 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.